Action BHC BAUSCH HEALTH COMPANIES INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Bausch Health Companies Inc.

Actions

BHC

CA0717341071

Marché Fermé - Nyse
Autres places de cotation
 22:00:01 06/05/2024 		Varia. 5j. Varia. 1 janv.
7,52 USD -3,84 % Graphique intraday de Bausch Health Companies Inc. -15,32 % -6,23 %
03/05 RBC abaisse l'objectif de Bausch Health à 10 $US et maintient sa performance sectorielle MT
02/05 Les actions de Bausch Health chutent après les résultats du 1er trimestre MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform
Bausch Health Announces First Quarter 2024 Results
Bausch Health Shares Fall Following Q1 Results
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance
Bausch: Q1 Earnings Snapshot
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
North American Morning Briefing : Stock Futures -2-
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
RBC Previews Bausch Health's Q1, Trims Target to US$11
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1
Bausch Health's Issuer Credit Rating Upgraded by S&P
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BHC
  4. Actualités Bausch Health Companies Inc.
  5. Autres langues